The mechanism of action of PARP inhibitors in SCLC appears to be different from other cancers such as ovarian and breast where sensitivity is in large part driven by a synthetic lethality with BRCA mutations or other mutations in genes regulating homologous recombination [40, 41]. This evidence concerns the gene PARP1 and small cell lung carcinoma.